Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 22;22(1):30. doi: 10.3390/ijms22010030

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Inhibition of mTORC2 reduced cell viability and proliferation dose-dependently. (A) The dose-dependent toxic effect of JR-AB2-011 (10–250 µM) was assessed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT) assay over 48 h in human and murine melanoma cells. Viability was plotted relative to untreated controls set to 100% (± standard deviation (SD) of three independent experiments). (B) bromdesoxyuridin BrdU incorporation assay indicates relevant inhibition of proliferation in human and murine melanoma cells by JR-AB2-011 (10–250 µM) after 48 h compared with the loss of cells in MTT assay. Treatment was normalized to untreated controls (± SD of three independent experiments). Asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) indicate significance between treatment and the control.